A5099843306- Bladder and Urothelial Cancer Treatments
- Gut microbiota and health
- Urinary Tract Infections Management
- Nonmelanoma Skin Cancer Studies
- Cervical Cancer and HPV Research
- Cancer Immunotherapy and Biomarkers
University of Split
2024-2025
Background and Objectives: This study explores the immunological landscapes of non-melanoma skin neoplasms (NMSNs), specifically keratoacanthoma (KA), squamous cell carcinoma (SCC), common warts (VV). Although benign, KA shares histological similarities with low-grade SCC. The tumor microenvironment (TME) plays a key role in progression, affecting angiogenesis, inflammation, immune evasion. Viral infections, particularly human papillomavirus (HPV), are linked to NMSN development, various HPV...
The gold standard for treating high-risk non-muscle-invasive bladder cancer involves the transurethral removal of cancerous tissue followed by BCG immunotherapy. So far, there is no reliable biomarker predicting efficacy and identifying patients who will or not respond to treatment. Emerging evidence suggests that urinary microbiota may play a crucial role in efficacy. This study aimed explore (i) changes during six induction cycles (ii) its potential predictive determining outcome To this...
Urinary bladder cancer (BC) inflicts a significant impairment of life quality and poses high mortality risk. Schistosoma haematobium infection can cause BC, the urinary microbiota BC patients differs from healthy controls. Importantly, intravesical instillation bacterium Bacillus Calmette-Guerin stands as foremost therapy for non-muscle invasive BC. Hence, studying receptors signaling molecules orchestrating bacterial recognition cellular response in context is paramount importance. Thus, we...